1043-3155 Pediatr Neurol Briefs pedneurbriefs Pediatr Neurol Briefs Pediatric Neurology Briefs Pediatr Neurol Briefs 2166-6482 1043-3155 2166-3155 Pediatric Neurology Briefs Publishers Chicago, IL, USA PNB-7-03-b 10.15844/pedneurbriefs-7-1-5 Seizure Disorders Neurology Pediatrics Nervous System Diseases Child Development Brain Diseases Neurosurgery Child Infant Felbamate in Lennox-Gastaut Syndrome http://orcid.org/0000-0002-0173-7931 Millichap J. Gordon MD 1 2 * Division of Neurology, Children's Memorial Hospital, Chicago, IL Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence: Dr. J. Gordon Millichap, E-mail: jgmillichap@northwestern.edu 01 1993 01 07 2016 7 1 3 4 Copyright: © 1993 The Author(s) 1993 This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome

The Felbamate Study Group report results in 73 patients ages 4 to 36 years with the Lennox-Gastaut syndrome, using a double-blind, placebo- controlled, add-on trial design.

 Lennox-Gastaut Syndrome Trial Design Felbamate-Treated Patients

The Felbamate Study Group report results in 73 patients ages 4 to 36 years with the Lennox-Gastaut syndrome, using a double-blind, placebo- controlled, add-on trial design. A maximum dosage of 45 mg/kg/body wt or 3600 mg/day was titrated within 14 days. Felbamate-treated patients had a 34% decrease in frequency of atonic seizures, as compared with a 9% decrease in those receiving placebo. The total frequency of seizures was decreased by 19% in felbamate-treated patients, as compared with a 4% increase in the placebo group. Side-effects were similar in the two groups. Anorexia, vomiting, and somnolence occurred more frequently in the felbamate group, whereas diarrhea occurred more frequently in the placebo group. [1]

COMMENT. Felbamate (2-phenyl-l,3-propanediol dicarbamate) appears to be effective in the treatment of various types of seizures associated with the Lennox-Gastaut syndrome. Side effects are typically mild or moderate in severity and require no change in dosage. According to parental observations, the overall quality of life is also improved by increased alertness and verbal responsiveness.

 Ritter FJ Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome N Engl J Med 1993 Jan 7 328 1 29 33 10.1056/NEJM199301073280105 8347179